CNS Pharmaceuticals, Inc.

NasdaqCM:CNSP

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 4.21 M

Share Price

USD 0.77

Avg Daily Volume

1,720,995

Change (1 day)

-7.31%

Change (1 year)

Change (YTD)

-88.56%

CNS Pharmaceuticals, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -88.56%

CNS Pharmaceuticals, Inc. Share Price Year-To-Date (YTD) return is -88.56% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

CNS Pharmaceuticals, Inc. 52-week low Share Price is USD 7.13 on June 20, 2025, which is 824.77% above the current Share Price.
CNS Pharmaceuticals, Inc. 52-week low Share Price is USD 0.77 on June 20, 2025, which is 0.00% below the current Share Price.
CNS Pharmaceuticals, Inc. average Share Price for the last 52 weeks is USD 1.68.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqCM: CNSP

CNS Pharmaceuticals, Inc.

CEO	Mr. John Michael Climaco Esq., J.D.
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	2100 West Loop South
Employees	4
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.